Main Menu

Publications Highlights View all by category

Types of Publications

Journal Articles

Nathan, P. Zweifel, M. Padhani, A.R. Koh, D.-. Ng, M. Collins, D.J. Harris, A. Carden, C. Smythe, J. Fisher, N. Taylor, N.J. Stirling, J.J. Lu, S.-. Leach, M.O. Rustin, G.J. Judson, I. (2012). Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin cancer res, Vol.18 (12), pp. 3428-3439.  show abstract

van der Graaf, W.T. Blay, J.-. Chawla, S.P. Kim, D.-. Bui-Nguyen, B. Casali, P.G. Schoffski, P. Aglietta, M. Staddon, A.P. Beppu, Y. Le Cesne, A. Gelderblom, H. Judson, I.R. Araki, N. Ouali, M. Marreaud, S. Hodge, R. Dewji, M.R. Coens, C. Demetri, G.D. Fletcher, C.D. Tos, A.P. Hohenberger, P. EORTC, S.T. (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, Vol.379 (9829), pp. 1879-1886.

Pacey, S. Wilson, R.H. Walton, M. Eatock, M.M. Hardcastle, A. Zetterlund, A. Arkenau, H.-. Moreno-Farre, J. Banerji, U. Roels, B. Peachey, H. Aherne, W. de Bono, J.S. Raynaud, F. Workman, P. Judson, I. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin cancer res, Vol.17 (6), pp. 1561-1570.  show abstract

Olmos, D. Postel-Vinay, S. Molife, L.R. Okuno, S.H. Schuetze, S.M. Paccagnella, M.L. Batzel, G.N. Yin, D. Pritchard-Jones, K. Judson, I. Worden, F.P. Gualberto, A. Scurr, M. de Bono, J.S. Haluska, P. (2010). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet oncol, Vol.11 (2), pp. 129-135.  show abstract

Lee, C.P. Payne, G.S. Oregioni, A. Ruddle, R. Tan, S. Raynaud, F.I. Eaton, D. Campbell, M.J. Cross, K. Halbert, G. Tracy, M. McNamara, J. Seddon, B. Leach, M.O. Workman, P. Judson, I. (2009). A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br j cancer, Vol.101 (11), pp. 1860-1868.  show abstract

O'Donnell, A. Faivre, S. Burris, H.A. Rea, D. Papadimitrakopoulou, V. Shand, N. Lane, H.A. Hazell, K. Zoellner, U. Kovarik, J.M. Brock, C. Jones, S. Raymond, E. Judson, I. (2008). Phase I pharmacokinetic and pharmacodynamic study of oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumours. J clin oncol, Vol.10 (26), pp. 1588-1595.


Pacey, S.C.Wilson, R.H.Walton, M.Martin, E.Moreno-Farre, J.Arkenau, H.T.Steinfeldt, H.Raynaud, F.Workman, P.Judson, I. (2007). A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors, MOL CANCER THER, Vol.6 (12), p.3332S.

In this section

Professional activities Publications